China Medical Devices Market 2026: NMPA Registration, VBP & Market Size

The Chinese medical devices market is estimated at USD 75–90 billion in 2026 — the world's second-largest, after the United States. China's device market is growing at approximately 8% CAGR, driven by rapid hospital infrastructure expansion (China's hospital bed count has grown from 4M in 2010 to over 8M), aging population dynamics, and government healthcare investment under Healthy China 2030. China has both a large import market (predominantly premium innovative devices) and a rapidly expanding domestic manufacturing sector across all device categories. NMPA (National Medical Products Administration) and NHSA (National Healthcare Security Administration) are the two institutions that most directly shape commercial outcomes in this market — NMPA controls whether and how fast a device can register, and NHSA controls the procurement and pricing conditions a registered device then faces in the public hospital channel. Companies sizing the opportunity typically model the import and domestic-manufacturing segments separately, since VBP exposure, tender scoring, and growth trajectories differ materially between the two.

NMPA (National Medical Products Administration) regulates medical devices in China through a three-class risk-based system: Class I (lowest risk — filing with local regulatory authority required); Class II (registration with provincial NMPA required; technical review); Class III (highest risk — national NMPA approval required; clinical evaluation/clinical trial data needed). Registration is required for imported and domestic devices. Imported devices require an NMPA certificate and a Resident Agent or local legal entity in China. Clinical evaluation requirements align partially with global standards but may require China-specific clinical data for Class III devices. NMPA has created a Priority Review pathway for innovative medical devices — the "创新医疗器械特别审查程序" (Special Review Procedure for Innovative Medical Devices).

Class III devices — implants, life-sustaining equipment, and other high-risk categories — are reviewed nationally by the Center for Medical Device Evaluation (CMDE) under NMPA. The full cycle from pre-submission communication through approval typically spans 18–36 months. Clinical evaluation can be satisfied through a clinical trial conducted in China, an accepted overseas clinical trial with supplementary Chinese data, or a literature-and-equivalence pathway for well-established device types. Class II filings handled at provincial level generally take 6–12 months and often rely on predicate equivalence without a full China trial.

NMPA's Special Review Procedure for Innovative Medical Devices (创新医疗器械特别审查程序) gives priority CMDE queuing to devices with core domestic intellectual property and a demonstrable clinical advantage. Qualifying applicants move faster through each review stage versus standard Class III queues. Eligibility is evidence-heavy: core IP ownership, clinical differentiation, and often early China development plans. Multinationals without China-origin IP typically cannot use this pathway as a pure import shortcut and instead rely on standard CMDE review plus localization strategy for post-approval tender scoring.

VBP (Volume-Based Procurement) has been extended from pharmaceuticals to medical devices with dramatic commercial impact. Key VBP device rounds: coronary stents (2020) — prices cut by ~93% from an average of CNY 13,000 to CNY 700 per stent; joint replacements — knee implants cut by ~84% in 2021; spine implants extended VBP 2023; cardiac electrophysiology catheters (2024). VBP device rounds typically require multi-year volume commitments from public hospitals in exchange for guaranteed procurement at VBP prices. For manufacturers, winning VBP secures volume but at minimal margins; losing means near-exclusion from public hospital procurement. This has driven import substitution acceleration — domestic manufacturers win more VBP rounds due to lower cost bases, putting international manufacturers under pressure.

VBP is not a one-time event. Categories already under national or provincial VBP face renewal tenders that re-set prices and awarded volume; adjacent categories (spine, EP catheters, IVD consumables, and further implant families) continue to be added. Renewal rounds often deepen price compression and raise the bar on local service and manufacturing footprints in scoring. Companies that won a prior round still need a renewal strategy — volume is not automatically rolled forward — and companies that lost need a private-hospital or provincial GPO path until the next window. Portfolio planning should assume progressive VBP expansion rather than a static list of included SKUs.

Private and premium hospital channels are a partial escape valve, not a full substitute for public volume. Private hospitals are less bound by national VBP award lists and can still procure higher-priced innovative or imported devices, especially in Tier-1 cities and for cash-pay or commercial-insurance episodes. Absolute volume, however, remains concentrated in public Grade III hospitals. Most multinationals therefore run a dual-channel model: defend or win VBP where required for public share, and protect margin in private/premium accounts with differentiated service, clinical education, and devices not yet under VBP. Import substitution catalogues can still influence private Grade III procurement preferences even when VBP pricing does not apply directly.

China's government-led import substitution policy (自主可控, or autonomous and controllable technology) is systematically replacing imported medical devices with domestically manufactured equivalents in public hospitals. The "Grade III Hospital Equipment Guidance Catalogue" (2021+) identifies device categories where domestic alternatives exist and recommends their use over imports. Priority domestically-produced device targets include: diagnostic imaging (CT, MRI, ultrasound — companies like United Imaging Healthcare, Mindray, Neusoft Medical), laboratory diagnostics (Mindray, Sysmex China, DAAN Gene), cardiac devices (MicroPort, Lepu Medical), and orthopaedic implants (Chunli Medical, Kanghui Holdings). International manufacturers with local production in China (joint ventures) may qualify as domestic products for procurement purposes.

The fastest-growing Chinese medical device segments are: AI-enabled diagnostics and medical AI (China leads globally in FDA/NMPA-cleared medical AI applications — companies including Infervision, Yitu Healthcare, Deep Pharma); robotic surgery (Chinese domestic surgical robot companies: MicroPort, Tinavi, Shenzhen Edge Medical competing with imported systems); continuous glucose monitoring (CGM penetration in China's 130M+ diabetic population is expanding rapidly); ophthalmic devices (refractive surgery, cataract, myopia — China has the world's highest myopia prevalence); and IVD consumables (domestic manufacturers expanding against international market leaders). These categories share a common trait: NMPA registration pathways for AI-enabled and robotic devices have matured enough over the past several years that regulatory uncertainty is no longer the primary growth constraint, shifting the commercial bottleneck toward hospital budget cycles, VBP scoring for consumable-heavy categories like CGM, and provincial-level adoption speed rather than approval timing.

Class II device registration is handled by provincial-level NMPA branches and generally takes 6–12 months, combining technical file review with a provincial Medical Device Technical Review Center assessment; a clinical trial is usually not required if the device can rely on an equivalence comparison to a predicate already registered in China. Class III devices — implants, life-sustaining equipment, and other high-risk categories — are reviewed nationally by the Center for Medical Device Evaluation (CMDE) under NMPA, and the full cycle from pre-submission communication through approval typically spans 18–36 months. Clinical evaluation for Class III devices can be satisfied through a clinical trial conducted in China, an accepted overseas clinical trial with supplementary Chinese data, or a literature-and-equivalence pathway for well-established device types. NMPA's Special Review Procedure for Innovative Medical Devices (创新医疗器械特别审查程序) shortens this timeline meaningfully for devices with core domestic intellectual property and a demonstrable clinical advantage, giving qualifying applicants priority queuing at each CMDE review stage.

Because import substitution and VBP scoring both favor domestically produced equipment, most international device manufacturers with meaningful China revenue have moved at least part of production onshore rather than serving the market purely through import. Common structures include wholly-owned local manufacturing subsidiaries, joint ventures with Chinese partners that hold their own NMPA manufacturing licenses, and technology-transfer or contract-manufacturing agreements with established domestic producers. Devices manufactured in China under these structures can register as domestic products for procurement purposes, improving eligibility for provincial tenders and Grade III Hospital Equipment Guidance Catalogue listings that otherwise favor local suppliers. Localization decisions are increasingly evaluated portfolio-wide: companies weigh the VBP volume protection and tender-scoring benefits of local production against the fixed cost of standing up NMPA-licensed manufacturing, and the answer often differs by device category and by how exposed that category already is to VBP.

Foreign manufacturers without a Chinese legal entity must appoint a China-based Resident Agent (代理人) — a company that holds legal responsibility for product registration maintenance, adverse-event reporting, and regulatory correspondence with NMPA and CMDE on the manufacturer's behalf. Import distribution additionally requires a licensed Chinese importer/distributor to handle customs clearance, and downstream sale to hospitals typically runs through provincial or regional distributors who hold the relevant device operating license (经营许可证) for the device classification involved. Class III devices and other higher-risk categories face additional post-market surveillance obligations, including periodic safety update reports and mandatory recall procedures administered through the Resident Agent. Many multinationals consolidate these functions with a single strategic distributor per region rather than a national distributor, reflecting how fragmented China's hospital procurement and tendering landscape remains at the provincial level.

BioNixus delivers medical device market research in China: regulator-aware access intelligence, hospital consumption analogues, physician and payer qualitative programmes, and launch evidence under EphMRA and BHBIA governance with GDPR-aligned fieldwork for multinational sponsors. Teams receive decision-ready outputs validated against national policy and institution-level adoption—not desk extrapolation from unrelated regions.

BioNixus supports China-based medical device companies expanding into GCC and MENA markets with SFDA and MOHAP regulatory intelligence, NUPCO and hospital procurement tracking in Saudi Arabia, UAE insurer and formulary research, physician panels across GCC countries, and comparative China versus GCC market intelligence. GCC expansion is a distinct service line with its own tender and access calendars—see our GCC pharmaceutical market report for regional context. Launch assumptions should be validated market by market rather than from a single Gulf average.